Patents Assigned to GW Research Limited
  • Patent number: 11446258
    Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the treatment of atonic seizures. In particular the CBD appears particularly effective in reducing atonic seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; Doose Syndrome; Aicardi syndrome; CDKL5 and Dup15q in comparison to other seizure types. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).
    Type: Grant
    Filed: September 16, 2021
    Date of Patent: September 20, 2022
    Assignee: GW Research Limited
    Inventors: Geoffrey Guy, Stephen Wright, Orrin Devinsky
  • Patent number: 11426362
    Abstract: The present invention relates to an oral formulation containing one or more cannabinoids. Preferably one or more cannabinoids dissolved in a solvent system consisting essentially of: a non-ionic surfactant and water together with other components which ensure the cannabinoids stability and the formulations palatability. Furthermore, the cannabinoid may be selected from one or more of cannabichromene (CBC), cannabichromenic acid (CBCV), cannabidiol (CBD), cannabidiolic acid (CBDA), cannabidivarin (CBDV), cannabigerol (CBG), cannabigerol propyl variant (CBGV), cannabicyclol (CBL), cannabinol (CBN), cannabinol propyl variant (CBNV), cannabitriol (CBO), tetrahydrocannabinol (THC), tetrahydrocannabinolic acid (THCA), tetrahydrocannabivarin (THCV) and tetrahydrocannabivarinic acid (THCVA).
    Type: Grant
    Filed: February 15, 2018
    Date of Patent: August 30, 2022
    Assignee: GW Research Limited
    Inventors: Stephen Wright, Jitinder Wilkhu
  • Patent number: 11419829
    Abstract: The present invention relates to the use of cannabidiol (CBD) in combination with an agonist of 5-HT2B receptors. Such a combination provides protection against the adverse effects caused by agonists of 5-HT2B receptors. The invention further relates to the use of CBD in combination5 with an amphetamine or amphetamine derivative in the treatment of epilepsy. In one embodiment the CBD is used in combination with the amphetamine derivative fenfluramine to produce a significant reduction in seizures. Preferably the CBD used is in the form of a highly purified extract of cannabis such that the CBD is present at greater than 98% of the total extract (w/w) and the other components of the extract are characterised. In particular the cannabinoid10 tetrahydrocannabinol (THC) has been substantially removed, to a level of not more than 0.15% (w/w) and the propyl analogue of CBD, cannabidivarin, (CBDV) is present in amounts of up to 1%. Alternatively, the CBD may be a synthetically produced CBD.
    Type: Grant
    Filed: October 1, 2018
    Date of Patent: August 23, 2022
    Assignee: GW Research Limited
    Inventors: Benjamin Whalley, Geoffrey Guy, Volker Knappertz, Royston Gray, Rohini Rana
  • Patent number: 11406623
    Abstract: The present disclosure provides methods of treating tuberous sclerosis complex comprising administering cannabidiol and everolimus.
    Type: Grant
    Filed: October 25, 2021
    Date of Patent: August 9, 2022
    Assignee: GW Research Limited
    Inventors: Geoffrey Guy, Volker Knappertz, Eduardo Dunayevich, David Critchley
  • Patent number: 11400055
    Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the treatment of Tuberous Sclerosis Complex (TSC). In particular the TSC is treatment resistant and is characterised by generalised seizures or focal seizures with impairment. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).
    Type: Grant
    Filed: June 7, 2021
    Date of Patent: August 2, 2022
    Assignee: GW Research Limited
    Inventors: Geoffrey Guy, Stephen Wright, Elizabeth Thiele
  • Patent number: 11390437
    Abstract: The invention relates to pharmaceutical formulations, and more particularly to formulations containing cannabinoids for administration via a pump action spray. In particular, the invention relates to pharmaceutical formulations, for use in administration of lipophilic medicaments via mucosal surfaces, comprising: at least one lipophilic medicament, a solvent and a co-solvent, wherein the total amount of solvent and co-solvent present in the formulation is greater than 55% wt/wt of the formulation and the formulation is absent of a self emulsifying agent and/or a fluorinated propellant.
    Type: Grant
    Filed: October 1, 2020
    Date of Patent: July 19, 2022
    Assignee: GW Research Limited
    Inventor: Brian Anthony Whittle
  • Patent number: 11357741
    Abstract: The present invention relates to the use of cannabidiol (CBD) in the treatment of focal seizures. In one embodiment the patients suffering from focal seizures are children and young adults. CBD appears particularly effective in reducing focal seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; CDKL5; Neuronal ceroid lipofuscinoses (NCL); febrile infection related epilepsy syndrome (FIRES); Aicardi syndrome and brain abnormalities in comparison to other seizure types. Significantly CBD additionally is very effective in the reduction of a sub-type of focal seizures, focal seizures with impairment.
    Type: Grant
    Filed: June 4, 2020
    Date of Patent: June 14, 2022
    Assignee: GW Research Limited
    Inventors: Geoffrey Guy, Stephen Wright, Orrin Devinsky
  • Patent number: 11311498
    Abstract: The present disclosure relates to the use of cannabidiol (CBD) in the treatment of absence seizures. In particular, the disclosure relates to the use of CBD for reducing absence seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; Doose Syndrome; CDKL5; Dup15q; Jeavons syndrome; Myoclonic Absence Epilepsy; Neuronal ceroid lipofuscinoses (NCL) and brain abnormalities. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).
    Type: Grant
    Filed: June 17, 2015
    Date of Patent: April 26, 2022
    Assignee: GW Research Limited
    Inventors: Geoffrey Guy, Stephen Wright, Orrin Devinsky
  • Patent number: 11291631
    Abstract: The present invention relates to a cannabinoid containing oral solution. Preferably the oral solution comprises a cannabinoid, a lipid solvent, a sweetener and ethanol, characterised in that the sweetener is an ultrahigh potency sweetener.
    Type: Grant
    Filed: June 29, 2017
    Date of Patent: April 5, 2022
    Assignee: GW Research Limited
    Inventor: Harshit Shah
  • Patent number: 11229612
    Abstract: The present invention relates to parenteral cannabinoid formulations, and more particularly to cannabinoid containing intravenous (IV) formulations. Preferably the parenteral containing formulation comprises a cannabinoid; an isotonic agent; a surfactant; and one or more stability enhancers. Furthermore the cannabinoid may be selected from one or more of cannabichromene (CBC), cannabichromenic acid (CBCV), cannabidiol (CBD), cannabidiolic acid (CBDA), cannabidivarin (CBDV), cannabigerol (CBG), cannabigerolpropyl variant (CBGV), cannabicyclol (CBL), cannabinol (CBN), cannabinol propyl variant (CBNV), cannabitriol (CBO), tetrahydrocannabinol (THC), tetrahydrocannabinolic acid (THCA), tetrahydrocannabivarin (THCV) and tetrahydrocannabivarinic acid (THCVA).
    Type: Grant
    Filed: June 29, 2017
    Date of Patent: January 25, 2022
    Assignee: GW Research Limited
    Inventors: Stephen Wright, Jitinder Wilkhu
  • Patent number: 11207292
    Abstract: Cannabidiol (CBD) is a cannabinoid designated chemically as 2-[(1R,6R)-3-Methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-1,3-benzenediol. Its empirical formula is C21H30O2 and its molecular weight is 314.46. CBD is a cannabinoid that naturally occurs in the Cannabis sativa L. plant. CBD is a white to pale yellow crystalline solid which is insoluble in water and soluble in organic solvents. The present invention encompasses the surprising recognition that certain CBD preparations which are prepared from a botanical origin are more effective in treating diseases or disorders than preparations of CBD which are synthetic or purified to the extent no other impurities in the form of other cannabinoids are present. Prior CBD compositions have been prepared such that no psychoactive components, e.g., tetrahydrocannabinol (THC), remain in the final CBD preparation. Surprisingly, the absence of such minor impurities reduces the efficacy of CBD treatment.
    Type: Grant
    Filed: September 3, 2020
    Date of Patent: December 28, 2021
    Assignee: GW Research Limited
    Inventors: Geoffrey Guy, Volker Knappertz, Benjamin Whalley, Marie Woolley-Roberts, James Brodie, Katarzyna Lach-Falcone, Alan Sutton, Royston Gray, Rohini Rajyalaxmi Rana
  • Patent number: 11160757
    Abstract: The present disclosure provides a microparticulate comprising one or more cannabinoids and a pH dependent release polymer. In embodiments, the one or more cannabinoids are present in an amount ranging from 10% w/w to about 50% w/w. In embodiments, the pH dependent release polymer is present in an amount ranging from ranging from about 5% w/w to about 85% w/w.
    Type: Grant
    Filed: October 12, 2020
    Date of Patent: November 2, 2021
    Assignee: GW Research Limited
    Inventors: Jitinder Wilkhu, Alan Silcock
  • Patent number: 11160795
    Abstract: The present disclosure provides methods of treating tuberous sclerosis complex comprising administering cannabidiol and everolimus.
    Type: Grant
    Filed: March 1, 2021
    Date of Patent: November 2, 2021
    Assignee: GW Research Limited
    Inventors: Geoffrey Guy, Volker Knappertz, Eduardo Dunayevich, David Critchley
  • Patent number: 11154516
    Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the reduction of total convulsive seizure frequency in the treatment of “treatment-resistant epilepsy” (TRE). In particular, the disclosure relates to the use of CBD of treating TRE when the TRE is Dravet syndrome; myoclonic absence seizures or febrile infection related epilepsy syndrome (FIRES). The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).
    Type: Grant
    Filed: December 11, 2020
    Date of Patent: October 26, 2021
    Assignee: GW Research Limited
    Inventors: Geoffrey Guy, Stephen Wright, Orrin Devinsky
  • Patent number: 11154517
    Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the treatment of atonic seizures. In particular the CBD appears particularly effective in reducing atonic seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; Doose Syndrome; Aicardi syndrome; CDKL5 and Dup15q in comparison to other seizure types. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).
    Type: Grant
    Filed: April 27, 2021
    Date of Patent: October 26, 2021
    Assignee: GW Research Limited
    Inventors: Geoffrey Guy, Stephen Wright, Orrin Devinsky
  • Patent number: 11147783
    Abstract: The present invention relates to the use of a therapeutically effective amount of cannabidiolic acid (CBDA) in the treatment of epilepsy. In one embodiment the CBDA is used in the treatment of generalised seizures, preferably tonic-clonic seizures. Preferably the CBDA used is in the form of a botanical drug substance in which the CBDA content is greater than 60%, and most preferably, it is a highly purified extract of cannabis such that the CBDA is present at greater than 95%, through 96% and 97% to most preferably, greater than 98% of the total extract (w/w) and the other components of the extract are characterised. In particular the cannabinoids tetrahydrocannabinol (THC) or tetrahydrocannabinol acid (THCA) have been substantially removed. Alternatively, the CBDA may be synthetically produced.
    Type: Grant
    Filed: July 29, 2016
    Date of Patent: October 19, 2021
    Assignee: GW Research Limited
    Inventors: Colin Stott, Nicholas Jones, Robin Williams, Benjamin Whalley
  • Patent number: 11147776
    Abstract: The present invention relates to the use of 7-hydroxy-cannabidol (7-OH-CBD) and/or 7-hydroxy-cannabidivarin (7-OH-CBDV) in the treatment of epilepsy. Preferably the cannabinoid metabolites are isolated from plants to produce a highly purified extract or can be reproduced synthetically.
    Type: Grant
    Filed: October 3, 2019
    Date of Patent: October 19, 2021
    Assignee: GW Research Limited
    Inventors: Colin Stott, Nick Jones, Benjamin Whalley, Gary Stephens, Claire Williams
  • Publication number: 20210308072
    Abstract: The present invention relates to the use of a combination of two different cannabinoids in the treatment of leukaemia. The combination of CBD with THC appears to be particularly effective in reducing cell number in this disease. Preferably the cannabinoids are used in the form of an extract of cannabis such that many of the naturally occurring compounds are co-extracted with the THC or CBD. Alternatively, the cannabinoids are present in the form of a highly purified extract of cannabis, wherein the CBD or THC are present at greater than 98% of the total extract (w/w) and the other components of the extract are characterized. Alternatively, the CBD and THC may be synthetically produced. A specific ratio of CBD and THC such as 10:1 to 1:10 (CBD:THC) or more preferably between 2:1 to 1:2 (CBD:THC) may be used.
    Type: Application
    Filed: April 15, 2021
    Publication date: October 7, 2021
    Applicant: GW Research Limited
    Inventors: Stephen Wright, Wai Liu, Katherine Scott, Angus Dalgleish
  • Patent number: 11096905
    Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the treatment of atonic seizures. In particular the CBD appears particularly effective in reducing atonic seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; Doose Syndrome; Aicardi syndrome; CDKL5 and Dup15q in comparison to other seizure types. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).
    Type: Grant
    Filed: March 11, 2021
    Date of Patent: August 24, 2021
    Assignee: GW Research Limited
    Inventors: Geoffrey Guy, Stephen Wright, Orrin Devinsky
  • Patent number: 11065209
    Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the treatment of Tuberous Sclerosis Complex (TSC). In particular the TSC is treatment resistant and is characterised by generalised seizures or focal seizures with impairment. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).
    Type: Grant
    Filed: January 12, 2021
    Date of Patent: July 20, 2021
    Assignee: GW Research Limited
    Inventors: Geoffrey Guy, Stephen Wright, Elizabeth Thiele